Early-generation trial of Ebola, Marburg vaccine candidates positive

December 23, 2014 4:30 PM

2 0

Results of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses, the first to be completed in an African country, showed that they were safe and induced immune responses in healthy Ugandan adult volunteers.

Developed by National Institute of Allergy and Infectious Diseases (NIAID) funded researchers, the experimental vaccines (called DNA vaccines) were predecessors to a next-generation candidate vaccine, called the NIAID/GSK Ebola vaccine, which is currently in clinical development. The NIAID/GSK vacci...

Read more

To category page